Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Atenolol Clear all
Completed No phase listed Observational Accepts healthy volunteers Results available

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol

NCT05794997
View directory record Official record
Conditions
Hypertension
Interventions
Propranolol or Carvedilol, Atenolol, Bisoprolol or Sotalol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
817,337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 18, 2026, 2:47 PM EDT
Completed Not applicable Interventional Results available

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

NCT01117454
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
Flecainide Acetate, Placebo, Beta blocker
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 18, 2026, 2:47 PM EDT
Withdrawn Not applicable Interventional

Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

NCT01009944
View directory record Official record
Conditions
Hypertension
Interventions
Lisinopril, Atenolol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 18, 2026, 2:47 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans

NCT00145210
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol and Atenolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2008 · Synced Oct 18, 2026, 2:47 PM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomic Evaluation of Antihypertensive Responses

NCT00246519
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Atenolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
17 Years to 65 Years
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 18, 2026, 2:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Atenolol 100mg Tablets Under Fasting Conditions

NCT00775580
View directory record Official record
Conditions
Healthy
Interventions
Atenolol 100mg Tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Chapell Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Oct 18, 2026, 2:47 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

NCT02467400
View directory record Official record
Conditions
Osteoporosis, Age-Related
Interventions
Atenolol, Nebivolol, Propranolol, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 18, 2026, 2:47 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

NCT04755764
View directory record Official record
Conditions
Systolic Hypertension, Pregnancy Related, Diastolic Hypertension, Cardiac Output, Low, Cardiac Output, High
Interventions
Labetalol, Atenolol, Nifedipine
Drug
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 18, 2026, 2:47 PM EDT
Completed Phase 4 Interventional

N-of-1 for Beta-Blockers in Cardiac Amyloidosis

NCT05019027
View directory record Official record
Conditions
Cardiac Amyloidosis, Heart Diseases, TTR Cardiac Amyloidosis
Interventions
Beta blocker
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 2:47 PM EDT
Terminated Phase 3 Interventional Results available

AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study

NCT00589303
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
FDA approved rate and rhythm control drugs, AV Node ablation and device implant
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Evansville, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 18, 2026, 2:47 PM EDT
Not listed Early Phase 1 Interventional

Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients

NCT03105661
View directory record Official record
Conditions
Obesity, Morbid, Preeclampsia
Interventions
Labetalol Hydrochloride 200 mg, NIFEdipine 60 mg, Atenolol 25 mg
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 18, 2026, 2:47 PM EDT
Recruiting Phase 4 Interventional

A Preliminary Study for INFORMED

NCT05585125
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Diseases
Interventions
Beta blocker
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 18, 2026, 2:47 PM EDT
Terminated Phase 4 Interventional Results available

Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes

NCT00925119
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Atenolol
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 18, 2026, 2:47 PM EDT
Completed Not applicable Interventional

Cognitive/Cerebrovascular Consequences of HTN Treatment

NCT00151138
View directory record Official record
Conditions
Hypertension
Interventions
Atenolol (drug), Lisinopril (drug)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
35 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2007 · Synced Oct 18, 2026, 2:47 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 18, 2026, 2:47 PM EDT
Completed Phase 4 Interventional Results available

Impact of Beta-blockers on Physical Function in HFpEF

NCT04767061
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
Interventions
Beta blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 18, 2026, 2:47 PM EDT
Completed Phase 2 Interventional

A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension

NCT00200421
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol and Atenolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2005 · Synced Oct 18, 2026, 2:47 PM EDT
Withdrawn Phase 3 Interventional

Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome

NCT01361087
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Blood draw
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Months to 24 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 18, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Atenolol for the Prevention of Osteoporosis (APO)

NCT04905277
View directory record Official record
Conditions
Healthy
Interventions
Atenolol 50 MG, Placebo
Drug
Lead sponsor
Sundeep Khosla, M.D.
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
Scarborough, Maine • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 18, 2026, 2:47 PM EDT
Withdrawn Phase 2 Interventional

4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

NCT03578354
View directory record Official record
Conditions
Vestibular Migraine, Migraine Disorders, Vestibular Diseases
Interventions
4-aminopyridine, Atenolol, Placebo
Drug · Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 18, 2026, 2:47 PM EDT
Completed Phase 3 Interventional Results available

Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome

NCT00723801
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Atenolol, Losartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 18, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

NCT00158093
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Atenolol, Moxifloxacin
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 12, 2005 · Synced Oct 18, 2026, 2:47 PM EDT
Enrolling by invitation Phase 4 Interventional

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

NCT07298993
View directory record Official record
Conditions
Heart Failure, HFpEF, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Placebo (matching), Beta-blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 2:47 PM EDT
Completed Phase 4 Interventional Results available

Black Education and Treatment of Hypertension (BEAT HTN)

NCT00661895
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Lisinopril, Lisinopril and Hydrochlorothiazide, Nifedipine XL, Metoprolol tartrate, Atenolol, Valsartan, Doxazosin, Clonidine, Hydralazine, Metoprolol succinate, Amlodipine
Drug
Lead sponsor
Creighton University
Other
Eligibility
25 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Oct 18, 2026, 2:47 PM EDT